Axa’s Arbutus Biopharma ABUS Stock Holding History

Axa’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-535,644	Closed	-$2.68M	–	1342
2018 Q1	$2.68M	Sell	535,644 -5,490	-1%	-$29.1K	0.01%	797
2017 Q4	$2.73M	Sell	541,134 -34,134	-6%	-$200K	0.01%	789
2017 Q3	$3.57M	Sell	575,268 -205,999	-26%	-$881K	0.02%	707
2017 Q2	$2.81M	Sell	781,267 -27,862	-3%	-$95.9K	0.01%	727
2017 Q1	$2.63M	Buy	809,129 +1,111	+0.1%	+$3.08K	0.01%	726
2016 Q4	$1.98M	Buy	808,018 +15,437	+2%	+$44.9K	0.01%	764
2016 Q3	$2.73M	Buy	792,581 +223	+0%	+$871	0.01%	689
2016 Q2	$2.76M	Buy	792,358 +11,062	+1%	+$46.8K	0.01%	683
2016 Q1	$3.23M	Hold	781,296	–	–	0.01%	660
2015 Q4	$3.48M	Sell	781,296 -16,423	-2%	-$90K	0.02%	655
2015 Q3	$4.86M	Buy	797,719 +375,974	+89%	+$3.33M	0.02%	581
2015 Q2	$5M	Buy	421,745 +170,944	+68%	+$2.6M	0.02%	598
2015 Q1	$4.38M	Buy	+250,801	New	+$5.14M	0.02%	635

Other funds holding ABUS

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Axa's ABUS Position: Q2 2018 in Review

Axa sold out of Arbutus Biopharma (ABUS) in Q2 2018, closing a stake of 535,644 shares — an estimated $2.68M sold.

Axa first reported a position in ABUS in Q1 2015 and held it in 13 quarters. The position peaked at $5M in Q2 2015. 71 funds tracked by Wall St. Rank hold ABUS as of Q2 2018.

Axa reported no remaining Arbutus Biopharma position as of Q2 2018 after selling out during the quarter.
Axa sold 535,644 Arbutus Biopharma shares in Q2 2018, an estimated $2.68M.
Axa first reported a position in Arbutus Biopharma in Q1 2015 and held it in 13 quarters.
Axa's Arbutus Biopharma position peaked at $5M in Q2 2015.
71 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2018.

Based on Axa's 13F filing for Q2 2018, filed 13 Aug 2018.